Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Astellas Pharma Inc has announced that, in the US phase II clinical trial of FG-2216

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Astellas Pharma Inc.Adverse Event of FG-2216 for the Treatment of Anemia. Media Release: 7 May 2007. Available from: URL: http://www.astellas.com

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Astellas Pharma Inc has announced that, in the US phase II clinical trial of FG-2216. React. Wkly. 1151, 3 (2007). https://doi.org/10.2165/00128415-200711510-00007

    Download citation

    Keywords

    • Public Health
    • Clinical Trial
    • Hepatitis
    • Marketing
    • Fulminant Hepatitis